ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Wednesday, May 20, 2015

Submitted by

Mark Ferguson

Source

Source Name: Lancet Oncology

Source URL: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970168-3/fu…

Author(s)

Joe Y Chang, Suresh Senan, Marinus A Paul, Reza J Mehran, Alexander V Louie, Peter Balter, Harry J M Groen, Stephen E McRae, Joachim Widder, Lei Feng, Ben E E M van den Borne, Mark F Munsell, Coen Hurkmans, Donald A Berry, Erik van Werkhoven, John J Kresl, Anne-Marie Dingemans, Omar Dawood, Cornelis J A Haasbeek, Larry S Carpenter, Katrien De Jaeger, Ritsuko Komaki, Ben J Slotman, Egbert F Smit, Jack A Roth

A pooled analysis of outcomes from two randomized trials involving SBRT or surgery for operable patients with clinical early stage NSCLC was performed. The number of patients was small (58 total) and the follow-up was a median of 35-40 mos. Overall 3-year survival was better in the SBRT group (95% vs 79%; p=0.037) whereas recurrence free survival did not differ between the groups. Grade 4 complications or death occurred in 48% of surgical patients (1 mortality) and in none of the SBRT patients.